Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Gemma Salvadó, Rik Ossenkoppele, Nicholas J. Ashton, et al.
EMBO Molecular Medicine (2023) Vol. 15, Iss. 5
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Donanemab in Early Symptomatic Alzheimer Disease
John R. Sims, Jennifer A. Zimmer, Cynthia Evans, et al.
JAMA (2023) Vol. 330, Iss. 6, pp. 512-512
Open Access | Times Cited: 1185
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 538
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Nicholas J. Ashton, Wagner S. Brum, Guglielmo Di Molfetta, et al.
JAMA Neurology (2024) Vol. 81, Iss. 3, pp. 255-255
Open Access | Times Cited: 260
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Oskar Hansson, Kaj Blennow, Henrik Zetterberg, et al.
Nature Aging (2023) Vol. 3, Iss. 5, pp. 506-519
Open Access | Times Cited: 227
Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
Nicolas R Barthélemy, Gemma Salvadó, Suzanne E. Schindler, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1085-1095
Open Access | Times Cited: 169
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
Joseph Therriault, Marie Vermeiren, Stijn Servaes, et al.
JAMA Neurology (2022) Vol. 80, Iss. 2, pp. 188-188
Open Access | Times Cited: 160
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Kanta Horie, Gemma Salvadó, Nicolas R. Barthélemy, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1954-1963
Open Access | Times Cited: 120
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Wagner S. Brum, Nicholas Cullen, Shorena Janelidze, et al.
Nature Aging (2023) Vol. 3, Iss. 9, pp. 1079-1090
Open Access | Times Cited: 116
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
Niklas Mattsson, Lyduine E. Collij, Erik Stomrud, et al.
JAMA Neurology (2023) Vol. 81, Iss. 1, pp. 69-69
Closed Access | Times Cited: 67
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 58
The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease
Youjin Jung, Jessica S. Damoiseaux
Brain (2023) Vol. 147, Iss. 1, pp. 12-25
Open Access | Times Cited: 47
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, et al.
Nature Aging (2024) Vol. 4, Iss. 5, pp. 694-708
Open Access | Times Cited: 41
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Matthew R. Meyer, Kristopher M. Kirmess, Stephanie Eastwood, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3179-3192
Open Access | Times Cited: 40
Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
Javier Arranz, Nuole Zhu, Sara Rubio‐Guerra, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 36
Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
Joseph Therriault, Nicholas J. Ashton, Ilaria Pola, et al.
EBioMedicine (2024) Vol. 102, pp. 105046-105046
Open Access | Times Cited: 26
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Burak Arslan, Henrik Zetterberg, Nicholas J. Ashton
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 6, pp. 1063-1069
Open Access | Times Cited: 25
Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
Pascual Sánchez‐Juan, Elizabeth Valeriano-Lorenzo, Alicia Ruiz-González, et al.
Brain (2024) Vol. 147, Iss. 5, pp. 1667-1679
Open Access | Times Cited: 23
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Juan Lantero Rodrı́guez, Laia Montoliu‐Gaya, Andréa L. Benedet, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 22
Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
Przemysław R. Kac, Fernándo González‐Ortiz, Andreja Emeršič, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
Yoshiki Niimi, Shorena Janelidze, Kenichiro Sato, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 17
Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies
Alexa Pichet Binette, Chris Gaiteri, Malin Wennström, et al.
Nature Neuroscience (2024) Vol. 27, Iss. 10, pp. 1880-1891
Open Access | Times Cited: 17
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnostics
Hyemin Jang, Daeun Shin, Heejin Yoo, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 2
Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression
Wiesje Pelkmans, Mahnaz Shekari, Anna Brugulat‐Serrat, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 1, pp. 483-493
Open Access | Times Cited: 40
Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
Lei Yu, Patricia A. Boyle, Shorena Janelidze, et al.
Acta Neuropathologica (2023) Vol. 146, Iss. 1, pp. 1-11
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top